Quantcast
Last updated on April 17, 2014 at 9:20 EDT

Latest Cancer treatments Stories

2013-08-06 23:29:05

Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a new vaccine study beginning at North Shore-LIJ ‘s Brain Tumor Center. New York, NY (PRWEB) August 06, 2013 On August 6, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a new vaccine study beginning at North Shore-LIJ’s Brain Tumor Center. According to an August 1, 2013 article published on The Island Now, titled, “Brain...

2013-07-19 23:01:51

Jamie Reno, an award-winning journalist, cancer survivor and patient advocate, discussed on his blog in depth recent discoveries by a small biotech firm in San Diego that has made significant advancement in cancer research. San Diego, CA (PRWEB) July 19, 2013 Jamie Reno, an award-winning journalist, cancer survivor and patient advocate, discussed in depth the discoveries by a small biotech firm in San Diego that has been flying under the radar for the past decade. What’s the big...

2013-07-19 12:24:39

Immunovative Therapies Mirror EffectTM is a unique cancer treatment based on immune system manipulation. Immunovative Therapies says that this treatment creates the tumor-killing effect of bone marrow transplant without the toxic side effects. Immunovative Therapies, using this method, may create a whole new industry of medicine. NEW YORK, July 19, 2013 /PRNewswire-iReach/ -- Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd, a biotech company in Israel, describes a...

2013-07-17 23:18:07

For the 14th year in a row, The Leukemia & Lymphoma Society (LLS) aims to stomp out blood cancer through the Light The Night® (LTN) Walk (http://www.LightTheNight.org). White Plains, NY (PRWEB) July 17, 2013 For the 14th year in a row, The Leukemia & Lymphoma Society (LLS) aims to stomp out blood cancer through the Light The Night® (LTN) Walk (http://www.LightTheNight.org). The LTN Walk is a powerful and unique fundraising campaign of LLS, which brings together families...

2013-07-11 16:28:34

Cancer vaccines prime the immune system to attack cancer cells, decreasing tumor progression. IL-12p70, a molecule produced by certain types of immune cells, has been shown to reduce tumor progression, but delivering it as part of a cancer vaccine has been limited because of its toxicity in high doses. In the current issue of the Journal of Clinical Investigation, Dr. Beatriz Carreno and colleagues at Washington University report the results of a clinical trial that tested a vaccine to treat...

2013-07-11 16:05:38

Indication of considerable added benefit for overall survival / indications of greater harm from side effects The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could not stop the disease from progressing. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German...

2013-07-10 08:26:32

May enable treatment of patients previously deemed untreatable WESTMINSTER, Colo., July 10, 2013 /PRNewswire/ -- Case reports published in the Journal of Cardiovascular and Interventional Radiology found that by using the Surefire Infusion System, radioembolization could be successfully performed without the need to protect nearby blood vessels, a significant advance that may enable doctors to safely extend liver cancer treatment to patients who were previously deemed untreatable....

2013-07-09 21:24:33

New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia (ALL). Study results were published online today in Blood, the Journal of the American Society of Hematology (ASH). Approximately 25 to 30 percent of all adults with ALL, the second most common...

2013-07-09 12:27:34

WASHINGTON, July 9, 2013 /PRNewswire-USNewswire/ -- New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia (ALL). Study results were published online today in Blood, the Journal of the American Society of Hematology (ASH). Approximately 25...

2013-07-09 08:27:54

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, a biotech company in Israel, discusses a unique approach to cancer treatment, in which its cellular-based drugs stimulate the host immune system to target and kill malignant cells. NEW YORK, July 9, 2013 /PRNewswire-iReach/ -- The most promising way to develop curative treatment that eliminates every cancer cell in a patient, says Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., would be by...